Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX1KDM)

Drug Name
ABI-H0731 Drug Info
Synonyms
Vebicorvir; UNII-16F6055SMG; 16F6055SMG; 11-Oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide; 2090064-66-5; Vebicorvir [INN]; Vebicorvir [USAN]; SCHEMBL21250344; WHO 11201; Dibenzo(b,F)(1,4)thiazepine-8-carboxamide, 10,11-dihydro-11-oxo-N-((2-(trifluoromethyl)-5-thiazolyl)methyl)-, 5,5-dioxide
Indication
Disease Entry ICD 11 Status REF
Hepatitis B 1E51 Phase 2 [1]
Cross-matching ID
PubChem CID
139394142
CAS Number
CAS 2090064-66-5
TTD Drug ID
DMX1KDM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Hepatitis B virus Capsid protein (HBV C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
JNJ-56136379 DM9RW6H Hepatitis B 1E51 Phase 2 [3]
ABI-H2158 DM6X70G Hepatitis B 1E51 Phase 2 [4]
ABI-H3733 DM4TN6W Hepatitis B 1E51 Phase 1 [4]
EDP-514 DM8KRA3 Chronic HBV infection 1E51.0Z Phase 1 [5]
RG7907 DMKVIS5 Hepatitis B 1E51 Phase 1 [6]
ZM-H1505R DMX6AJ8 Hepatitis B 1E51 Phase 1 [7]
A204 DMF1LYP Hepatitis B virus infection 1E51.0 Phase 1 [8]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis B virus Capsid protein (HBV C) TTM42UJ CAPSD_HBVD3 Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03576066) A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection. U.S. National Institutes of Health.
2 Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166.
3 JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9.
4 Clinical pipeline report, company report or official report of Assembly Biosciences.
5 Clinical pipeline report, company report or official report of Enanta Pharmaceuticals.
6 Clinical pipeline report, company report or official report of Roche.
7 Clinical pipeline report, company report or official report of Shanghai Zhimeng Biopharma.
8 Clinical pipeline report, company report or official report of Klus Pharma